Over 70 million chest X-rays are done in the US each year. None of them report out major risk of osteoporotic fractures. We're in the era of opportunistic AI and not seizing the oportunities @NEJM_AI
https://t.co/1m2sdBJgYp
Eric Topol today:
The screening lesson on this slide is not the AI. It is that the highest-yield test is the one already in the chart. Seven years of papers, each pulling a different disease out of the same 10 seconds of ECG. #ScientificSessions26
En hipertensión resistente y/o no controlada, agregar espironolactona al manejo, fue la estrategia más eficiente; al ↓sistólica 12mmHg
Metaanálisis network de 30 ensayos clínicos
JACC 2026
https://t.co/hM8baJS7gR
📣 Targeted Assessment in High-Risk Patients With Diabetes to Identify Heart Failure (TARTAN-HF) 🔥
DESIGN
Prospective multicentre RCT in community-based clinics in Scotland
POPULATION
706 diabetics with 1 or more risk factors for HF: CKD, CAD, CVA, loop diuretic, COPD, PAD, AFib (excluding known HF or age <40)
INTERVENTION
NT-proBNP -> if ≥125 -> TTE
CONTROL
Usual care
OUTCOME #1
HF diagnosis @ 6 months: 25% vs. 1% (OR 58; NNT 5)
ESC 2021 criteria to diagnose HF
A. Typical symptom/sign of HF: Dyspnea, Orthopnea, PND, Fatigue on exertion, Ankle swelling, Peripheral edema, Ascites, Raised JVP, Rales, or S3
+
B. TTE evidence of cardiac dysfunction: LVEF <50% or LV diastolic dysfunction/raised LV filling pressures with NT-proBNP ≥125
OUTCOME #2
GDMT initiation @ 6 months: +53 vs. +3 patients started on SGLT2i
OUTCOME #3
QOL (KCCQ-12 OSS): 65.6/100 for HF diagnosed group vs. 89.6/100 for HF not diagnosed group
DISCUSSION
CKD and CAD were #1 qualifying risk factors for HF screening, dyspnea and fatigue were #1 qualifying diagnostic symptoms for HF diagnosis
Approx. 50% of NT-proBNPs were +ve -> 50% of those TTEs were +ve
Of the n=87 HF diagnoses among intervention patients: 81 pEF, 3 mrEF, 3 rEF
So what? If HF is diagnosed (sooner than later), there is evidence to support the beneficial initiation of SGLT2i, GLP-1RA, finerenone in pEF and BB, ARNI, MRA in rEF
https://t.co/WJfxRjkGJX
@JACCJournals@markcpetrie20@Kieranfdocherty
Just 10 days of bed rest reduces mitochondrial content by double digits in older adults while ROS production spikes. Function stays intact only because each mitochondrion works overtime.
A Journal of Physiology study tracked what happens to muscle mitochondria in 10 older men (average age 68) during 10 days of complete bed rest. This simulates what happens during hospitalization, illness recovery, or any period where you stop moving.
The findings show a temporary compensation that masks underlying damage.
Key findings:
• Mitochondrial quantity dropped significantly
• Damaging free radical production increased 62-65%
• Energy production capacity remained normal
• Each remaining mitochondrion worked harder to compensate
• Over 3,000 genes changed, with energy pathways shutting down
• Antioxidant defenses weakened while stress signals activated
After just 10 days of complete inactivity, older adults lost a substantial portion of their mitochondrial mass. Mitochondrial volume density measured by electron microscopy dropped significantly, and citrate synthase activity fell in parallel.
But here's the twist: total energy production stayed normal because the remaining mitochondria cranked up their individual output.
This sounds like good news. It's not.
The compensation comes at a cost. The mitochondria that survived started producing more reactive oxygen species, essentially damaging molecules that your cells normally neutralize with antioxidant systems. Production went up while the cleanup systems got weaker.
When damage production outpaces your ability to clear it, problems accumulate.
The gene expression data revealed what's happening. More than 3,000 genes changed their activity levels. Genes responsible for building new mitochondria and maintaining energy production all got dialed down. Meanwhile, emergency stress response genes activated.
Your muscle is essentially preparing for prolonged shutdown while trying to manage rising damage.
This pattern matters because it defines the sequence. Mitochondrial loss and oxidative damage happen first, within 10 days. Actual energy production failure comes later, after the compensation exhausts itself.
Previous studies in young adults showed they maintained their mitochondrial content after 10 days of bed rest. Older adults in this study lost it. The age-related difference in resilience to inactivity is significant.
Younger muscle can weather short periods of inactivity without shedding mitochondria. Older muscle starts losing them within days.
The practical implication: if you're over 65 and face a period of reduced activity from illness, injury, or hospitalization, mitochondrial decline starts almost immediately. The energy production numbers might look fine initially, but you're operating on fewer, overworked mitochondria producing more cellular damage.
Once you lose mitochondria, rebuilding them takes time and may be incomplete.
This explains why older adults often struggle to return to baseline function after hospitalization or illness. The visible problem is muscle weakness. The underlying driver is mitochondrial loss that happened in the first week or two of inactivity.
The intervention window is narrow. Maintaining some level of activity during periods that would otherwise be sedentary, protecting mitochondrial mass before it drops, matters more than trying to rebuild after the fact.
For healthy aging, the message is clear: consistency matters more as you age. Younger muscle tolerates gaps in activity. Older muscle doesn't have that buffer. A week or two of complete inactivity triggers changes that weeks or months of training built.
The decisions made during short periods of forced inactivity, whether you do simple resistance exercises in bed, walk as soon as possible, or stay completely sedentary, shape the mitochondrial foundation available when you try to resume normal activity.
Older muscle operates with less margin for error. The first 10 days of inactivity look deceptively manageable because energy production stays normal. The damage is happening at a level you can't feel yet.
Four weeks of wall squats reduced systolic blood pressure by nearly 10 points in adults with high blood pressure.
Researchers then compared continuing three sessions weekly with reducing to two, one, or none for another month. Systolic pressure remained roughly 7 mmHg below starting levels in the once- and twice-weekly groups. Continuing three sessions weekly produced the greatest reduction of about 14 mmHg. In those who stopped completely, blood pressure moved back toward baseline.
This fits with a previous analysis of randomized trials that identified isometric exercise, which involves holding a muscle contraction, as an effective way to lower resting blood pressure.
What interests me is the practical question - how much of an exercise benefit can we preserve when we temporarily have less time? This study suggests that reducing the frequency can retain part of the benefit for up to a month.
@Andrea25633402 I thought so too but ASTEROID was explicitly a statin-naïve population and its secondary QCA analysis still showed only a modest luminal change: mean percent diameter stenosis fell from 37.3% to 36.0% over 24 months (about 1.3 absolute percentage points, or 0.65% per year).
Patient: How fast will high-dose statin treatment regress my 70% stenosis?
Doctor: umm…
FLOWPROMOTE shed light on this, but before the “how fast”, let’s go over the “how”
1️⃣ Intensive statin therapy lowers circulating LDL, so less crosses into the wall to feed the plaque’s core.
2️⃣ Downregulates endothelial VCAM and ICAM, reducing monocyte recruitment.
3️⃣ Silences macrophages, releasing less VEGF for angiogenesis and intra-plaque hemorrhage.
4️⃣ Silenced macrophages release less MMP-9, so they stop chewing the plaque’s fibrous cap.
5️⃣ Stimulates smooth muscle cells to migrate in and lay down fresh collagen, rebuilding the cap.
6️⃣ Upregulates CCR7, letting lipid-laden foam cells leave the plaque and emigrate to lymph nodes.
7️⃣ Promotes calcification of residual plaque, making it denser and mechanically tougher.
8️⃣ Lowers tissue factor and calms platelets, so if a cap ever ruptures, the clot is smaller and more likely to lyse.
Regression is real: with IVUS changes in atheroma volume translating to roughly 1% diameter improvement per year, about 10% over a decade in a best-case scenario. But it can also be invisible, because a vessel often remodels inward as plaque shrinks. And it can be irrelevant, because a plaque that doesn’t rupture doesn’t need to disappear.
7️⃣ things I appreciate about this figure
1. Illustrating HR and 95% CI with forest plot
2. Color coding high risk 🍎 to low risk 🍏
3. Sorting from strongest to weakest effect
4. Including raw event rates and % on right
5. Rounding to the nearest % (🚫4.359%)
6. No cryptic abbreviations
7. High data density without visual clutter
👏 @JACCJournals@TIMIStudyGroup
The most important briefings of the day.
Karl Deisseroth, professor of bioengineering and of psychiatry and behavioral sciences, shares the news of his Nobel Prize with his kids.
The phase 3 clinical trials table of https://t.co/S5Fos6x81U (top trials DB of https://t.co/TEcnqoQcHd) now updated thanks to work by @tliu44.
- New approvals (eg Scholar Rock).
- Failed ph3s marked as such.
- Prev Ph2 programs now in ph3 added.
The pipeline progresses (slowly).
In our lecture series on aging, @FrailtyMD said something very instructive (paraphrasing here):
"We have to make an extra effort to distinguish between frailty and multi-morbidity, otherwise, we won't be able to intervene early!"
Majority of the deficit accumulation models, e-Frailty, ICD-based frailty indices, etc, measure cumulative comorbidity not frailty. Jon's imaging-based coreslicer (https://t.co/CmzFrAWAvO) is very impressive!!
@MichaelGNanna@heartwiselab
#innovation
😅 I found a frailty shout-out at the end of the recently published PAD guidelines
“endovascular (revascularization) options often suffice for less complex disease and are an option for frail patients also with complex lesions when surgery is unsuitable”
Agree/Disagree? How often does frailty tip the scale when deciding on revascularization strategy? @AeroMD
A pragmatic trial is not a fig leaf for sloppy methods with stale EHR data. The #PRECIS2 framework reminds us that effectiveness studies need intentional design, not just convenient shortcuts.
💬 Editorial by @JAMAplusTrials Editor in Chief Alison J. Huang, MD, MAS, Thomas G. Travison, PhD, and JAMA Senior Editor Derek C. Angus, MD, MPH:
#PragmaticTrials are intended to support real-world clinical decision-making, but the term is used inconsistently across studies. A pragmatic orientation may improve the applicability of #ClinicalTrials to routine care, yet it does not justify weaker methods or reduced rigor.
📣 This September’s JAMA+ Trials Theme of the Month examines ongoing confusion and debate in pragmatic trial research, including how eligibility, intervention delivery, outcome assessment, and analysis align with pragmatic goals. Clearer design and reporting may help clinicians and health systems judge whether trial findings are usable in practice.
🔗 https://t.co/mZSQqFEcae